Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Average Rating of “Moderate Buy” from Analysts

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given a consensus recommendation of “Moderate Buy” by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $14.8333.

Several equities analysts recently issued reports on KPTI shares. The Goldman Sachs Group set a $12.00 price target on Karyopharm Therapeutics in a report on Wednesday, December 17th. Piper Sandler restated an “overweight” rating and issued a $12.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Wall Street Zen upgraded shares of Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, November 8th. Royal Bank Of Canada reduced their price target on shares of Karyopharm Therapeutics from $30.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 4th. Finally, Cantor Fitzgerald initiated coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They set an “overweight” rating on the stock.

Institutional Trading of Karyopharm Therapeutics

Institutional investors have recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in Karyopharm Therapeutics by 101.2% in the 4th quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock valued at $1,382,000 after acquiring an additional 94,445 shares in the last quarter. Bank of America Corp DE grew its stake in Karyopharm Therapeutics by 26.8% in the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock valued at $726,000 after purchasing an additional 35,626 shares in the last quarter. Silverback Asset Management LLC increased its holdings in Karyopharm Therapeutics by 40.0% during the second quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock worth $302,000 after buying an additional 20,000 shares during the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at about $163,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Karyopharm Therapeutics during the 3rd quarter worth about $164,000. 66.44% of the stock is currently owned by institutional investors.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ:KPTI opened at $7.37 on Thursday. The company’s fifty day moving average is $6.86 and its 200-day moving average is $6.18. Karyopharm Therapeutics has a 52 week low of $3.51 and a 52 week high of $10.38. The company has a market capitalization of $134.94 million, a PE ratio of -0.51 and a beta of 0.21.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, February 12th. The company reported ($5.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.26) by ($3.45). The business had revenue of $34.08 million during the quarter, compared to analysts’ expectations of $33.16 million. On average, analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.